Next Article in Journal
Gageostatins A–C, Antimicrobial Linear Lipopeptides from a Marine Bacillus subtilis
Next Article in Special Issue
Cytotoxic Effects of Fascaplysin against Small Cell Lung Cancer Cell Lines
Previous Article in Journal
Bioactive Cembranoids, Sarcocrassocolides P–R, from the Dongsha Atoll Soft Coral Sarcophyton crassocaule
Previous Article in Special Issue
Trabectedin and Plitidepsin: Drugs from the Sea that Strike the Tumor Microenvironment
Open AccessReview

Fucoidan as a Marine Anticancer Agent in Preclinical Development

Department of Biochemistry, School of Medicine and Immune-Network Pioneer Research Center, Dong-A University, 32, Daesingongwon-ro, Seo-gu, Busan 602-714, Korea
Mar. Drugs 2014, 12(2), 851-870;
Received: 15 November 2013 / Revised: 31 December 2013 / Accepted: 10 January 2014 / Published: 28 January 2014
(This article belongs to the Collection Marine Compounds and Cancer)
Fucoidan is a fucose-containing sulfated polysaccharide derived from brown seaweeds, crude extracts of which are commercially available as nutritional supplements. Recent studies have demonstrated antiproliferative, antiangiogenic, and anticancer properties of fucoidan in vitro. Accordingly, the anticancer effects of fucoidan have been shown to vary depending on its structure, while it can target multiple receptors or signaling molecules in various cell types, including tumor cells and immune cells. Low toxicity and the in vitro effects of fucoidan mentioned above make it a suitable agent for cancer prevention or treatment. However, preclinical development of natural marine products requires in vivo examination of purified compounds in animal tumor models. This review discusses the effects of systemic and local administration of fucoidan on tumor growth, angiogenesis, and immune reaction and whether in vivo and in vitro results are likely applicable to the development of fucoidan as a marine anticancer drug. View Full-Text
Keywords: fucoidan; anticancer; preclinical; anticancer immunity; antiangiogenesis fucoidan; anticancer; preclinical; anticancer immunity; antiangiogenesis
MDPI and ACS Style

Kwak, J.-Y. Fucoidan as a Marine Anticancer Agent in Preclinical Development. Mar. Drugs 2014, 12, 851-870.

Show more citation formats Show less citations formats

Article Access Map by Country/Region

Only visits after 24 November 2015 are recorded.
Search more from Scilit
Back to TopTop